MP41-16 PEMBROLIZUMAB VS. CONVENTIONAL CHEMOTHERAPY AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN REAL-WORLD PRACTICE: A MULTICENTER RETROSPECTIVE STUDY

Takuma Narita,Shingo Hatakeyama,Kazuyuki Numakura,Mizuki Kobayashi,Yumina Muto,Mitsuru Saito,Toshikazu Tanaka,Daisuke Noro,Noriko Tokui,Takahiro Yoneyama,Yasuhiro Hashimoto,Tomonori Habuchi,Chikara Ohyama

MP41-16 PEMBROLIZUMAB VS. CONVENTIONAL CHEMOTHERAPY AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN REAL-WORLD PRACTICE: A MULTICENTER RETROSPECTIVE STUDY

2021

Takuma Narita
Shingo Hatakeyama
Kazuyuki Numakura
Mizuki Kobayashi
Yumina Muto
Mitsuru Saito
Toshikazu Tanaka
Daisuke Noro
Noriko Tokui
Takahiro Yoneyama
Yasuhiro Hashimoto
Tomonori Habuchi
Chikara Ohyama

INTRODUCTION AND OBJECTIVE:The clinical benefit of pembrolizumab as second-line therapy for advanced urothelial carcinoma (aUC) remains unclear in real-world practice. Hence, we retrospectively com...

Keywords:

Pembrolizumab
first line
Oncology
urothelial carcinoma
Chemotherapy
Medicine
conventional chemotherapy
Internal medicine
Retrospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations